BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 32437876)

  • 21. Drug Repurposing Strategies for Non-cancer to Cancer Therapeutics.
    Singhal S; Maheshwari P; Krishnamurthy PT; Patil VM
    Anticancer Agents Med Chem; 2022 Aug; 22(15):2726-2756. PubMed ID: 35301945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug repurposing for breast cancer therapy: Old weapon for new battle.
    Aggarwal S; Verma SS; Aggarwal S; Gupta SC
    Semin Cancer Biol; 2021 Jan; 68():8-20. PubMed ID: 31550502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug Repurposing for Cancer Therapy in the Era of Precision Medicine.
    K W To K; Cho WCS
    Curr Mol Pharmacol; 2022; 15(7):895-903. PubMed ID: 35156588
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anticancer Drug Discovery By Structure-Based Repositioning Approach.
    Modh DH; Kulkarni VM
    Mini Rev Med Chem; 2024; 24(1):60-91. PubMed ID: 37165589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overcoming cancer therapeutic bottleneck by drug repurposing.
    Zhang Z; Zhou L; Xie N; Nice EC; Zhang T; Cui Y; Huang C
    Signal Transduct Target Ther; 2020 Jul; 5(1):113. PubMed ID: 32616710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current progress and future perspectives of polypharmacology : From the view of non-small cell lung cancer.
    Karuppasamy R; Veerappapillai S; Maiti S; Shin WH; Kihara D
    Semin Cancer Biol; 2021 Jan; 68():84-91. PubMed ID: 31698087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities.
    Di J; Zheng B; Kong Q; Jiang Y; Liu S; Yang Y; Han X; Sheng Y; Zhang Y; Cheng L; Han J
    Mol Oncol; 2019 Oct; 13(10):2259-2277. PubMed ID: 31408580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Old wine in new bottles: Drug repurposing in oncology.
    Antoszczak M; Markowska A; Markowska J; Huczyński A
    Eur J Pharmacol; 2020 Jan; 866():172784. PubMed ID: 31730760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Repurposing antipsychotics of the diphenylbutylpiperidine class for cancer therapy.
    Shaw V; Srivastava S; Srivastava SK
    Semin Cancer Biol; 2021 Jan; 68():75-83. PubMed ID: 31618686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-Cancer Potential of Some Commonly Used Drugs.
    Kumari P; Dang S
    Curr Pharm Des; 2021; 27(45):4530-4538. PubMed ID: 34161206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repurposing some of the Well-known Non-steroid Anti-inflammatory Drugs (NSAIDs) for Cancer Treatment.
    Sousa SM; Xavier CPR; Vasconcelos MH; Palmeira A
    Curr Top Med Chem; 2023; 23(13):1171-1195. PubMed ID: 36717997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repurposing of drugs as STAT3 inhibitors for cancer therapy.
    Thilakasiri PS; Dmello RS; Nero TL; Parker MW; Ernst M; Chand AL
    Semin Cancer Biol; 2021 Jan; 68():31-46. PubMed ID: 31711994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds.
    Würth R; Thellung S; Bajetto A; Mazzanti M; Florio T; Barbieri F
    Drug Discov Today; 2016 Jan; 21(1):190-199. PubMed ID: 26456577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic repurposing screening in xenograft models identifies approved drugs with novel anti-cancer activity.
    Roix JJ; Harrison SD; Rainbolt EA; Meshaw KR; McMurry AS; Cheung P; Saha S
    PLoS One; 2014; 9(8):e101708. PubMed ID: 25093583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer.
    Nowak-Sliwinska P; Scapozza L; Ruiz i Altaba A
    Biochim Biophys Acta Rev Cancer; 2019 Apr; 1871(2):434-454. PubMed ID: 31034926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A medicinal chemistry perspective of drug repositioning: Recent advances and challenges in drug discovery.
    Pillaiyar T; Meenakshisundaram S; Manickam M; Sankaranarayanan M
    Eur J Med Chem; 2020 Jun; 195():112275. PubMed ID: 32283298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Computational Cell Cycle Profiling of Cancer Cells for Prioritizing FDA-Approved Drugs with Repurposing Potential.
    Lo YC; Senese S; France B; Gholkar AA; Damoiseaux R; Torres JZ
    Sci Rep; 2017 Sep; 7(1):11261. PubMed ID: 28900159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An Insight into Drug Repositioning for the Development of Novel Anti-Cancer Drugs.
    Bhattarai D; Singh S; Jang Y; Hyeon Han S; Lee K; Choi Y
    Curr Top Med Chem; 2016; 16(19):2156-68. PubMed ID: 26881715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prince and the pauper. A tale of anticancer targeted agents.
    Dueñas-González A; García-López P; Herrera LA; Medina-Franco JL; González-Fierro A; Candelaria M
    Mol Cancer; 2008 Oct; 7():82. PubMed ID: 18947424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug repurposing a compelling cancer strategy with bottomless opportunities: Recent advancements in computational methods and molecular mechanisms.
    Dash R; Yadav M; Biswal J; Samanta S; Sharma T; Mohapatra S
    Indian J Pharmacol; 2023; 55(5):322-331. PubMed ID: 37929411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.